Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Drug

CARsgen Therapeutics’ Saikaize and CT071 Show Strong Results in EHA Clinical Trials

Fineline Cube Jun 17, 2024

CARsgen Therapeutics, a biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 2171), has...

Company Drug

RemeGen’s Disitamab Vedotin Shows Positive Results in Phase III Trial for HER2 Positive Breast Cancer

Fineline Cube Jun 14, 2024

RemeGen Ltd (HKG: 9995), a biopharmaceutical company based in China, has announced positive results from...

Company Deals

AbbVie Strikes Deal with FutureGen for Global Rights to Next-Gen TL1A Antibody FG-M701

Fineline Cube Jun 14, 2024

AbbVie (NYSE: ABBV), a biopharmaceutical giant based in the US, has announced a licensing agreement...

Company Deals

BeiGene to Terminate Partnership with NewBridge Pharmaceuticals for MENA Region

Fineline Cube Jun 14, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company based in China, has...

Company Deals

Ethypharm Expands in China’s IBD Market with Acquisition of Mesalazine Suppository

Fineline Cube Jun 14, 2024

Ethypharm, a France-based pharmaceutical company, has announced that its Chinese subsidiary, Shanghai Ethypharmaceuticals Ltd, has...

Company Deals

Sihuan’s Xuanzhu Biopharmaceutical Strikes Licensing Deal with Livzon Pharmaceutical for Fadanafil

Fineline Cube Jun 14, 2024

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has declared that its subsidiary, Xuanzhu Biopharmaceutical Co.,...

Company Drug

CStone Pharmaceuticals Gets NMPA Green Light for Local Production of Gavreto

Fineline Cube Jun 14, 2024

CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has announced that it...

Company Drug

Innovent Biologics’ IBI363 Shows Promising Results in Phase Ia/Ib Trial for Advanced Solid Tumors

Fineline Cube Jun 14, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...

Company Deals

Ronovo Surgical Secures Over RMB 300 Million in Series B to Globalize Surgical Robot

Fineline Cube Jun 14, 2024

Shanghai-based surgical robotics specialist, Ronovo Surgical, has reportedly raised over RMB 300 million (USD 41.3...

Company Deals Drug

Cellbri Bio Secures Nearly RMB 200 Million in Series B Financing to Boost CGT Commercialization

Fineline Cube Jun 14, 2024

Shenzhen Cellbri Bio-Innovation Technology Co., Ltd, a prominent player in China’s cell and gene therapy...

Company Deals Medical Device

Zhejiang Dian Diagnostics Partners with Quest Diagnostics to Advance Alzheimer’s Disease Blood Tests

Fineline Cube Jun 14, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostics company based in China, has...

Company Drug

Apeloa Pharmaceutical Partners with Beijing Highthink for CRO Services on Semaglutide Generic

Fineline Cube Jun 14, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has forged a strategic partnership...

Company Deals

GSK Partners with Ochre Bio to Access Liver Data for Hepatology Therapy Development

Fineline Cube Jun 14, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has entered into an agreement with fellow...

Company Drug

Pfizer’s Gene Therapy for Duchenne Muscular Dystrophy Misses Late-Stage Trial Endpoints

Fineline Cube Jun 14, 2024

Pfizer Inc. (NYSE: PFE) has announced that a late-stage clinical trial for its investigational gene...

Company Drug

AstraZeneca’s Farxiga Receives FDA Approval for Pediatric Type-2 Diabetes Treatment

Fineline Cube Jun 14, 2024

The US Food and Drug Administration (FDA) has granted regulatory approval to AstraZeneca (AZ; NASDAQ:...

Company Drug

Amgen’s Prolia Secures NMPA Approval for Treating Glucocorticoid-Induced Osteoporosis in High-Risk Patients

Fineline Cube Jun 14, 2024

Biopharmaceutical giant Amgen has received marketing approval from China’s National Medical Products Administration (NMPA) for...

Policy / Regulatory

NHSA Seeks Public Input on National Reimbursement Drug List Adjustments

Fineline Cube Jun 14, 2024

The National Healthcare Security Administration (NHSA) has unveiled the adjustment plan for the National Reimbursement...

Company Drug

Eli Lilly’s Baqsimi Gains NMPA Approval for Diabetes Hypoglycemia Treatment

Fineline Cube Jun 13, 2024

The National Medical Products Administration (NMPA) in China has granted approval to Eli Lilly &...

Company Deals

Chia Tai Tianqing and China Resource Medicine Commercial Holdings Join Forces for Pharmaceutical Industry Expansion

Fineline Cube Jun 13, 2024

Chia Tai Tianqing, a renowned name in the Chinese healthcare industry, has forged a strategic...

Company Drug

Boehringer Ingelheim’s Survodutide Earns Breakthrough Designation for MASH Treatment in China

Fineline Cube Jun 13, 2024

Boehringer Ingelheim (BI), the German pharmaceutical colossus, has declared that it has been granted Breakthrough...

Posts pagination

1 … 337 338 339 … 658

Recent updates

  • Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A
  • WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion
  • Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
  • Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
  • Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A

Company

WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.